Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.
Researchers at Arizona State University are experimenting with a compound that might prevent Alzheimer’s and other neurodegenerative diseases, such as Parkinson’s disease, and potentially Down syndrome.
Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.
Researchers with Massachusetts General Hospital have identified some crosstalk communication between TREM2 and CD33, two genes that play a role in inflammation and Alzheimer’s disease.
Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.
Researchers at the RIKEN Center for Brain Science identified a new protein that might make the connection between amyloid plaques and tau in Alzheimer’s patients.
The Bill & Melinda Gates Foundation and Jeff Bezos’ Day One Fund teamed up to donate $15 million to the Diagnostics Accelerator as part of the Alzheimer’s Drug Discovery Foundation.
Having second-degree or third-degree relatives with Alzheimer’s raises a person’s risk of developing the disease, a new study suggests.
Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.
German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.